Astria Therapeutics, Inc. - Common Stock, par value $0.001 per share (ATXS)

Q: What does CUSIP 04635X102 represent in this 13F holders report?

CUSIP 04635X102 is the security identifier for ATXS - Astria Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held ATXS - Astria Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q2 2023?

76 institutional investors reported ATXS - Astria Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q2 2023. Use the holders table for investor-level position and value details.

CUSIP: 04635X102

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 57,127,897
Total 13F shares: 24,666,745
Share change: +1,243,587
Total reported value: $205,474,768
Put/Call ratio: 74%
Price per share: $8.33
Number of holders: 76
Value change: +$6,090,240
Number of buys: 46
Number of sells: 35

Quarterly Holders Quick Answers

What is CUSIP 04635X102?
CUSIP 04635X102 identifies ATXS - Astria Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2023
Previous quarter: Q1 2023

Recent filing periods for CUSIP 04635X102:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ATXS - Astria Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.

Institutional Holders of Astria Therapeutics, Inc. - Common Stock, par value $0.001 per share (ATXS) as of Q2 2023

As of 30 Jun 2023, Astria Therapeutics, Inc. - Common Stock, par value $0.001 per share (ATXS) was held by 76 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 24,666,745 shares. The largest 10 holders included FMR LLC, PERCEPTIVE ADVISORS LLC, Fairmount Funds Management LLC, Deep Track Capital, LP, Vivo Capital, LLC, BlackRock Inc., VANGUARD GROUP INC, Driehaus Capital Management LLC, Altium Capital Management LP, and Cormorant Asset Management, LP. This page lists 76 institutional shareholders reporting positions in this security for the Q2 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2023 vs Q1 2023 Across Filers

Q1 2023 holders

Q2 2023 holders

Holder diff

Investor	Q1 2023 Shares	Q2 2023 Shares	Share Diff	Share Chg %	Q1 2023 Value $	Q2 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.